0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Editorial | 
Peter M. Nilsson, MD, PhD; Fredrik H. Nystrom, MD, PhD
JAMA. 2014;312(8):795-796. doi:10.1001/jama.2014.10058.

Original Investigation |  FREE
Richard J. McManus, FRCGP; Jonathan Mant, MD; M. Sayeed Haque, PhD; et al.
JAMA. 2014;312(8):799-808. doi:10.1001/jama.2014.10057.
Includes: Supplemental Content

Health Agencies Update | 
Bridget M. Kuehn, MSJ
JAMA. 2014;311(24):2473. doi:10.1001/jama.2014.7063.

Viewpoint | 
Samuel T. Wilkinson, MD; Deepak Cyril D’Souza, MBBS, MD
JAMA. 2014;311(23):2377-2378. doi:10.1001/jama.2014.6175.

Original Investigation |  FREE
Christianne L. Roumie, MD, MPH; Robert A. Greevy, PhD; Carlos G. Grijalva, MD, MPH; et al.
JAMA. 2014;311(22):2288-2296. doi:10.1001/jama.2014.4312.
Includes: Supplemental Content

Review | 
Amisha Wallia, MD, MS; Mark E. Molitch, MD
JAMA. 2014;311(22):2315-2325. doi:10.1001/jama.2014.5951.
Includes: CME, Supplemental Content

Medical News & Perspectives | 
Bridget M. Kuehn, MSJ
JAMA. 2014;311(21):2159-2160. doi:10.1001/jama.2014.5090.

Viewpoint | 
Bruce M. Psaty, MD, PhD; Noel S. Weiss, MD, DrPH
JAMA. 2014;311(5):461-462. doi:10.1001/jama.2013.284203.

The Medical Letter on Drugs and Therapeutics | 
JAMA. 2014;311(5):521. doi:10.1001/jama.2014.208.

Original Investigation |  FREE
Leonard V. Sacks, MBBCh; Hala H. Shamsuddin, MD; Yuliya I. Yasinskaya, MD; et al.
JAMA. 2014;311(4):378-384. doi:10.1001/jama.2013.282542.
Includes: CME, Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson, MD; Gary K. Schwartz, MD; Mary Louise Keohan, MD; et al.
JAMA Oncology
Brief Report  | 
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma
M. Estela Martinez-Escala, MD; Timothy M. Kuzel, MD; Jason B. Kaplan, MD; et al.
JAMA Oncology
Invited Commentary  | 
Romidepsin Therapy Over 5 Years in a Clinical Setting—Real-World Experience
Susan E. Bates, MD; Larisa J. Geskin, MD
JAMA Oncology
Research Letter  | 
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
Lecia V. Sequist, MD, MPH; Zofia Piotrowska, MD; Matthew J. Niederst, PhD; et al.